Stoke Therapeutics, Inc.

US$26.54As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:STOKHealthcare
Country USA
PE (Fwd) •••
TSR 7Y CAGR (1.28%)
Div yield —
ROE (73.62%)
Biotechnology
Beta (5Y) 1.38
PE TTM —
TSR TTM (11.65%)
Mkt cap US$1.736B
ROIC (575.69%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$26
(2.08%)
(67.44%)
Hold 12|10|5|6|11
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.26
0.27
0.28
0.31
13.73%
19.32%
14.37%
28.91%
Revenue$M
122.4
125.9
122.6
129.4
5.03%
8.23%
1.81%
10.38%
Peers (US$1.736B)
Cap (US$)
PE
1.745B
—
Capital
TTM
5Y
10Y
Leveragex
1.392
0.207
0.178
EBIT/Intx
0.953
0.988
1.149
Own earn%
(420.16)
28.29
20.29
Sh yield%
14.76
28.40
28.77
Owners
Insiders/Inst%
7.05
37.57
Short interest%
5.29
SBC / revenue%
0.74
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
10
Op margin range%
15–24
$1 testx
—
Incr. ROIC%
4